Merck Reaches Hepatitis C Market With Zepatier
This article was originally published in The Pink Sheet Daily
Executive Summary
Grazoprevir/elbasvir doublet has a much narrower indication than other hepatitis C therapies, but it could have an edge in those subpopulations.
You may also be interested in...
No More Nucs: Merck & Co. Cedes HCV Market To Gilead, AbbVie
Pharma ends HCV development, pulling plug on next-generation two-drug and three-drug combos for hepatitis C and rendering the $3.9bn buyout of Idenix in 2014 a failed gambit.
Cambridge Vision Achieved, AstraZeneca Looks To Realize ‘Pipeline 2’ Ambitions
Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.
Pfizer/BioNTech’s Comirnaty Supply Agreements Unaffected Despite EU Green Light For Under-12s
Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.